New York, According to a new market research report published by Global Insight Services Single-cell Analysis Market is expected to reach US$ XX bn by 2031. Report includes in-depth segmentation and market size data by categories, product types, applications, and

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a Fireside Chat event during the Credit Suisse 31st Annual Healthcare Conference on Tuesday, November 8, 2022, at 11:00 AM (PST). A link to a live webcast of the event will be available in the Investor Relations

Bio-Rad Laboratories, Inc. (NYSE:NYSE:BIO) Q3 2022 Earnings Conference Call October 27, 2022, 17:00 ET Company Participants Edward Chung - VP, IR Ilan Daskal - EVP & CFO Andrew Last -…

Bio-Rad Labs press release (BIO): Q3 Non-GAAP EPS of $2.60 misses by $0.17.Revenue of $680.8M (-8.9% Y/Y) misses by $1.9M.For the full-year 2022, the company continues to…

Life Sciences tool makers including Repligen (RGEN) and Bio-Rad Laboratories (BIO) are down in Wednesday trading after competitor Sartorius (SARTF) said it was seeing "a swift…

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24%. However, in the longer term, BIO stock, with 65% returns from levels se

Rumors are circulating that life sciences/diagnostics companies Qiagen and Bio-Rad may merge. Read why a deal may face a difficult time getting off the ground.

A rumored matchup between Bio-Rad Laboratories and Qiagen is unlikely, an analyst said Tuesday as BIO stock fell for a second straight day.

Shares of Qiagen N.V. (NYSE:QGEN) gained 3.2%, while shares of Bio-Rad Laboratories (NYSE:BIO) were down 8.4% yesterday. The share price movement was followed by a Wall Street Journal news report that said both companies could potentially merge in a deal worth $10 billion approximately. Based in the Netherlands, QIAGEN NV is a holding company that provides sample and assay technology to transform biological samples into valuable molecular insights. Based in the U.S., Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications.

Bio-Rad Laboratories Inc (NYSE: BIO ) is reportedly in talks to merge with Qiagen NV (NYSE: QGEN ), but any agreement isn''t likely for another few weeks or more, or it may not happen at all. A deal between Qiagen and Bio-Rad would be the latest tie-up in the medical-diagnostic market. The sector has grown as the pandemic helped increase demand for testing. According to the Wall Street Journal report , … Full story available on Benzinga.com

At the close of the New York Stock Exchange, the Dow Jones was down 0.32%, the S&P 500 was down 0.75% and the NASDAQ Composite was down 1.04%. Walgreens Boots Alliance Inc was the leading gainer in the Dow Jones Index today, up 1.32 points or 4.33% to close at 31.84. Merck & Company Inc rose 2.88 points or 3.29% to close at 90.48. Boeing Co rose 2.11 points or 1.63% to close at 131.90. The losers were Salesforce Inc, which shed 4.65 points or 3.09% to end the session at 145.64. Microsoft Corporation was up 2.13% or 4.99 points to close at 229.25, while Walt Disney Company was down 2.06% or 2.00 points to close at 95. 16. Leading gainers among the S&P 500 index components in today''s trading were Walgreens Boots Alliance Inc, which rose 4.33% to 31.84, Moderna Inc, which gained 3.44% to close at 123.42, and also shares of McCormick & Company Incorporated, which rose 3.30% to end the session at 75.86. The biggest losers were Wynn Resorts Limited, which shed 12.25% to close at 64.14. Shares of Bio-Rad Laboratories Inc shed 8.33% to end the session at 393.19.

It''s the circle of life for life-sciences companies. The California-based Bio-Rad Laboratories and the Netherlands-based Qiagen are deep in talks…

TOKYO (dpa-AFX) - Bio-Rad Laboratories Inc. (BIO) is in talks to merge with Qiagen NV (QGEN) in a deal worth more than $10 billion, the Wall Street Journal reported, citing people familiar with th…

Bio-Rad Labs and Qiagen in Combination Talks - WSJ

Diagnostics company Bio-Rad Laboratories (BIO) is in talks with competitor Qiagen N.V. to combine, The Wall Street Journal reported.

https://www.investing.com/news/pro/update-biorad-labs-in-talks-to-combine-with-qiagen--wsj-432SI-2908597

California-based diagnostics company Bio-Rad Laboratories is in talks to merge with Qiagen NV , according to a Wall Street Journal report on Monday. (Reporting by Bhanvi Satija in Bengaluru; Editing by Vinay Dwivedi)

Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.

Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.

The Protein Assays Market study combines a quantitative investigation of local markets with a novel viewpoint on the target market. The study includes information on the market''s size, as well as its strengths and weaknesses, important players, a sector overview,